Ieq Capital LLC Boosts Position in Haleon plc (NYSE:HLN)

Ieq Capital LLC grew its stake in shares of Haleon plc (NYSE:HLN) by 16.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,251 shares of the company’s stock after purchasing an additional 4,079 shares during the quarter. Ieq Capital LLC’s holdings in Haleon were worth $270,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Synovus Financial Corp grew its stake in Haleon by 0.8% during the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock worth $1,575,000 after buying an additional 1,216 shares during the last quarter. Greenleaf Trust grew its position in shares of Haleon by 8.4% during the fourth quarter. Greenleaf Trust now owns 17,225 shares of the company’s stock worth $164,000 after acquiring an additional 1,333 shares during the last quarter. Baron Wealth Management LLC increased its holdings in shares of Haleon by 4.3% in the 4th quarter. Baron Wealth Management LLC now owns 33,632 shares of the company’s stock valued at $321,000 after acquiring an additional 1,381 shares during the period. Peapack Gladstone Financial Corp raised its position in Haleon by 3.2% in the 3rd quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company’s stock valued at $474,000 after purchasing an additional 1,390 shares during the last quarter. Finally, CENTRAL TRUST Co boosted its stake in Haleon by 19.1% during the 4th quarter. CENTRAL TRUST Co now owns 8,932 shares of the company’s stock worth $85,000 after purchasing an additional 1,430 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on HLN shares. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.95.

Haleon Stock Up 3.9 %

HLN stock opened at $10.18 on Friday. The stock has a market capitalization of $46.06 billion, a PE ratio of 29.93, a price-to-earnings-growth ratio of 2.82 and a beta of 0.28. The company has a fifty day moving average of $9.59 and a 200-day moving average of $9.83. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a one year low of $7.89 and a one year high of $10.80.

Haleon (NYSE:HLN) last announced its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, analysts expect that Haleon plc will post 0.43 EPS for the current year.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.